{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:22:49Z","timestamp":1793125369878,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021778","name":"Agencia Nacional de Promoci\u00f3n de la Investigaci\u00f3n, el Desarrollo Tecnol\u00f3gico y la Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PICT 2018-1866"],"award-info":[{"award-number":["PICT 2018-1866"]}],"id":[{"id":"10.13039\/501100021778","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00262-023-03448-w","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T03:29:13Z","timestamp":1682047753000},"page":"2687-2700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phenotypic and functional analysis in HER2+\u2009targeted therapy of human NK cell subpopulation according to the expression of Fc\u03b5RI\u03b3 and NKG2C in breast cancer patients"],"prefix":"10.1007","volume":"72","author":[{"given":"Mar\u00eda B.","family":"Bordignon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayel\u00e9n I.","family":"Pesce Viglietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda P.","family":"Juli\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda B.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"R\u00f6lle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Mand\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Sabatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ostinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manglio M.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda M.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mordoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Fainboim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella M.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"3448_CR1","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 30:1194\u20131220. https:\/\/doi.org\/10.1093\/annonc\/mdz173","journal-title":"Ann Oncol"},{"key":"3448_CR2","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","volume":"69","author":"W Scheuer","year":"2009","unstructured":"Scheuer W, Friess T, Burtscher H et al (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69:9330\u20139336. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4597","journal-title":"Cancer Res"},{"key":"3448_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","volume":"18","author":"S Park","year":"2010","unstructured":"Park S, Jiang Z, Mortenson ED et al (2010) The therapeutic effect of anti-HER2\/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18:160\u2013170. https:\/\/doi.org\/10.1016\/j.ccr.2010.06.014","journal-title":"Cancer Cell"},{"key":"3448_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim S-B et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724\u2013734. https:\/\/doi.org\/10.1056\/NEJMoa1413513","journal-title":"N Engl J Med"},{"key":"3448_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3389\/fimmu.2020.00740","volume":"11","author":"SW de Taeye","year":"2020","unstructured":"de Taeye SW, Bentlage AEH, Mebius MM et al (2020) Fc\u03b3R Binding and ADCC Activity of Human IgG Allotypes. Front Immunol 11:740. https:\/\/doi.org\/10.3389\/fimmu.2020.00740","journal-title":"Front Immunol"},{"key":"3448_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2326-6066.CIR-15-0120","volume":"3","author":"DJ DiLillo","year":"2015","unstructured":"DiLillo DJ, Ravetch JV (2015) Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol Res 3:704\u2013713. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0120","journal-title":"Cancer Immunol Res"},{"key":"3448_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fimmu.2011.00018","volume":"2","author":"E Vivier","year":"2011","unstructured":"Vivier E, Ugolini S (2011) Natural killer cells: from basic research to treatments. Front Immunol 2:18. https:\/\/doi.org\/10.3389\/fimmu.2011.00018","journal-title":"Front Immunol"},{"key":"3448_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1172\/JCI200215950","volume":"110","author":"R Parihar","year":"2002","unstructured":"Parihar R, Dierksheide J, Hu Y, Carson WE (2002) IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 110:983\u2013992. https:\/\/doi.org\/10.1172\/JCI200215950","journal-title":"J Clin Invest"},{"key":"3448_CR9","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/0008-5472.CAN-16-2774","volume":"77","author":"VA Gall","year":"2017","unstructured":"Gall VA, Philips AV, Qiao N et al (2017) Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res 77:5374\u20135383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2774","journal-title":"Cancer Res"},{"key":"3448_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nri.2015.9","volume":"16","author":"A Cerwenka","year":"2016","unstructured":"Cerwenka A, Lanier LL (2016) Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol 16:112\u2013123. https:\/\/doi.org\/10.1038\/nri.2015.9","journal-title":"Nat Rev Immunol"},{"key":"3448_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.it.2016.01.005","volume":"37","author":"A R\u00f6lle","year":"2016","unstructured":"R\u00f6lle A, Brodin P (2016) Immune adaptation to environmental influence: the case of NK cells and HCMV. Trends Immunol 37:233\u2013243. https:\/\/doi.org\/10.1016\/j.it.2016.01.005","journal-title":"Trends Immunol"},{"key":"3448_CR12","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1182\/blood-2012-10-459545","volume":"121","author":"V B\u00e9ziat","year":"2013","unstructured":"B\u00e9ziat V, Liu LL, Malmberg J-A et al (2013) NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 121:2678\u20132688. https:\/\/doi.org\/10.1182\/blood-2012-10-459545","journal-title":"Blood"},{"key":"3448_CR13","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2004-05-2058","volume":"104","author":"M Gum\u00e1","year":"2004","unstructured":"Gum\u00e1 M, Angulo A, Vilches C et al (2004) Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104:3664\u20133671. https:\/\/doi.org\/10.1182\/blood-2004-05-2058","journal-title":"Blood"},{"key":"3448_CR14","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","volume":"119","author":"B Foley","year":"2012","unstructured":"Foley B, Cooley S, Verneris MR et al (2012) Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C + natural killer cells with potent function. Blood 119:2665\u20132674. https:\/\/doi.org\/10.1182\/blood-2011-10-386995","journal-title":"Blood"},{"key":"3448_CR15","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.4049\/jimmunol.1402281","volume":"194","author":"M Costa-Garcia","year":"2015","unstructured":"Costa-Garcia M, Vera A, Moraru M et al (2015) Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus. J Immunol 194:2715\u20132724. https:\/\/doi.org\/10.4049\/jimmunol.1402281","journal-title":"J Immunol"},{"key":"3448_CR16","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.4049\/jimmunol.1201964","volume":"189","author":"B Foley","year":"2012","unstructured":"Foley B, Cooley S, Verneris MR et al (2012) Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol 189:5082\u20135088. https:\/\/doi.org\/10.4049\/jimmunol.1201964","journal-title":"J Immunol"},{"key":"3448_CR17","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.4049\/jimmunol.1302053","volume":"192","author":"M Della Chiesa","year":"2014","unstructured":"Della Chiesa M, Falco M, Bertaina A et al (2014) Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C\u2212\/\u2212\u2009umbilical cord blood. J Immunol 192:1471\u20131479. https:\/\/doi.org\/10.4049\/jimmunol.1302053","journal-title":"J Immunol"},{"key":"3448_CR18","doi-asserted-by":"publisher","first-page":"14725","DOI":"10.1073\/pnas.1110900108","volume":"108","author":"S Lopez-Verg\u00e8s","year":"2011","unstructured":"Lopez-Verg\u00e8s S, Milush JM, Schwartz BS et al (2011) Expansion of a unique CD57 +NKG2C hi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A 108:14725\u201314732. https:\/\/doi.org\/10.1073\/pnas.1110900108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3448_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1182\/blood-2008-05-157354","volume":"112","author":"TW Kuijpers","year":"2008","unstructured":"Kuijpers TW, Baars PA, Dantin C et al (2008) Human NK cells can control CMV infection in the absence of T cells. Blood 112:914\u2013915","journal-title":"Blood"},{"key":"3448_CR20","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1002\/eji.201343773","volume":"43","author":"A Muntasell","year":"2013","unstructured":"Muntasell A, L\u00f3pez-Monta\u00f1\u00e9s M, Vera A et al (2013) NKG2C zygosity influences CD94\/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus. Eur J Immunol 43:3268\u20133278. https:\/\/doi.org\/10.1002\/eji.201343773","journal-title":"Eur J Immunol"},{"key":"3448_CR21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1399-0039.2012.01911.x","volume":"80","author":"M Moraru","year":"2012","unstructured":"Moraru M, Ca\u00f1izares M, Muntasell A et al (2012) Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction. Tissue Antigens 80:184\u2013187. https:\/\/doi.org\/10.1111\/j.1399-0039.2012.01911.x","journal-title":"Tissue Antigens"},{"key":"3448_CR22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.celrep.2016.04.005","volume":"15","author":"LL Liu","year":"2016","unstructured":"Liu LL, Landskron J, Ask EH et al (2016) Critical role of CD2 co-stimulation in adaptive natural killer cell responses revealed in NKG2C-deficient humans. Cell Rep 15:1088\u20131099. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.005","journal-title":"Cell Rep"},{"key":"3448_CR23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/intimm\/dxs080","volume":"24","author":"I Hwang","year":"2012","unstructured":"Hwang I, Zhang T, Scott JM et al (2012) Identification of human NK cells that are deficient for signaling adaptor FcR\u03b3 and specialized for antibody-dependent immune functions. Int Immunol 24:793\u2013802. https:\/\/doi.org\/10.1093\/intimm\/dxs080","journal-title":"Int Immunol"},{"key":"3448_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3389\/fimmu.2018.01031","volume":"9","author":"C Capuano","year":"2018","unstructured":"Capuano C, Battella S, Pighi C et al (2018) Tumor-targeting anti-CD20 antibodies mediate in vitro expansion of memory natural killer cells: impact of CD16 affinity ligation conditions and in vivo priming. Front Immunol 9:1031. https:\/\/doi.org\/10.3389\/fimmu.2018.01031","journal-title":"Front Immunol"},{"key":"3448_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/eji.201141826","volume":"42","author":"V B\u00e9ziat","year":"2012","unstructured":"B\u00e9ziat V, Dalgard O, Asselah T et al (2012) CMV drives clonal expansion of NKG2C + NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol 42:447\u2013457. https:\/\/doi.org\/10.1002\/eji.201141826","journal-title":"Eur J Immunol"},{"key":"3448_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.immuni.2015.02.008","volume":"42","author":"H Schlums","year":"2015","unstructured":"Schlums H, Cichocki F, Tesi B et al (2015) Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42:443\u2013456. https:\/\/doi.org\/10.1016\/j.immuni.2015.02.008","journal-title":"Immunity"},{"key":"3448_CR27","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.4049\/jimmunol.1203034","volume":"190","author":"T Zhang","year":"2013","unstructured":"Zhang T, Scott JM, Hwang I, Kim S (2013) Cutting edge: antibody-dependent memory-like NK cells distinguished by FcR\u03b3 deficiency. J Immunol 190:1402\u20131406. https:\/\/doi.org\/10.4049\/jimmunol.1203034","journal-title":"J Immunol"},{"key":"3448_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.02140","volume":"9","author":"EP Juli\u00e1","year":"2018","unstructured":"Juli\u00e1 EP, Amante A, Pampena MB et al (2018) Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against triple negative breast cancer cells. Front Immunol 9:1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2018.02140","journal-title":"Front Immunol"},{"key":"3448_CR29","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu T, Vilo J (2015) ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res 43:W566\u2013W570. https:\/\/doi.org\/10.1093\/nar\/gkv468","journal-title":"Nucleic Acids Res"},{"key":"3448_CR30","doi-asserted-by":"publisher","first-page":"e2034","DOI":"10.1002\/rmv.2034","volume":"29","author":"M Zuhair","year":"2019","unstructured":"Zuhair M, Smit GSA, Wallis G et al (2019) Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol 29:e2034. https:\/\/doi.org\/10.1002\/rmv.2034","journal-title":"Rev Med Virol"},{"key":"3448_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.it.2016.09.005","volume":"37","author":"TA Fehniger","year":"2016","unstructured":"Fehniger TA, Cooper MA (2016) Harnessing NK cell memory for cancer immunotherapy. Trends Immunol 37:877\u2013888. https:\/\/doi.org\/10.1016\/j.it.2016.09.005","journal-title":"Trends Immunol"},{"key":"3448_CR32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature07665","volume":"457","author":"JC Sun","year":"2009","unstructured":"Sun JC, Beilke JN, Lanier LL (2009) Adaptive immune features of natural killer cells. Nature 457:557\u2013561. https:\/\/doi.org\/10.1038\/nature07665","journal-title":"Nature"},{"key":"3448_CR33","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-20-3418","volume":"27","author":"H Cho","year":"2021","unstructured":"Cho H, Kim KH, Lee H et al (2021) Adaptive natural killer cells facilitate effector functions of daratumumab in multiple myeloma. Clin cancer Res an Off J Am Assoc Cancer Res 27:2947\u20132958. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3418","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"key":"3448_CR34","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/bloodadvances.2020002440","volume":"5","author":"AB Bigley","year":"2021","unstructured":"Bigley AB, Spade S, Agha NH et al (2021) Fc\u03b5RI\u03b3-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma. Blood Adv 5:3021\u20133031. https:\/\/doi.org\/10.1182\/bloodadvances.2020002440","journal-title":"Blood Adv"},{"key":"3448_CR35","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.3389\/fimmu.2019.02865","volume":"10","author":"KH Kim","year":"2019","unstructured":"Kim KH, Yu HT, Hwang I et al (2019) Phenotypic and functional analysis of human NK cell subpopulations according to the expression of Fc\u03b5RI\u03b3 and NKG2C. Front Immunol 10:2865. https:\/\/doi.org\/10.3389\/fimmu.2019.02865","journal-title":"Front Immunol"},{"key":"3448_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10549-012-2287-y","volume":"136","author":"MP Roberti","year":"2012","unstructured":"Roberti MP, Rocca YS, Amat M et al (2012) IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. Breast Cancer Res Treat 136:659\u2013671. https:\/\/doi.org\/10.1007\/s10549-012-2287-y","journal-title":"Breast Cancer Res Treat"},{"key":"3448_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3389\/fimmu.2018.00486","volume":"9","author":"A Kurioka","year":"2018","unstructured":"Kurioka A, Cosgrove C, Simoni Y et al (2018) CD161 defines a functionally distinct subset of pro-inflammatory natural killer cells. Front Immunol 9:486. https:\/\/doi.org\/10.3389\/fimmu.2018.00486","journal-title":"Front Immunol"},{"key":"3448_CR38","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3389\/fimmu.2017.01544","volume":"8","author":"A Muntasell","year":"2017","unstructured":"Muntasell A, Cabo M, Servitja S et al (2017) Interplay between natural killer cells and anti-HER2 antibodies: perspectives for breast cancer immunotherapy. Front Immunol 8:1544. https:\/\/doi.org\/10.3389\/fimmu.2017.01544","journal-title":"Front Immunol"},{"key":"3448_CR39","doi-asserted-by":"publisher","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","volume":"67","author":"S Varchetta","year":"2007","unstructured":"Varchetta S, Gibelli N, Oliviero B et al (2007) Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67:11991\u201311999. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2068","journal-title":"Cancer Res"},{"key":"3448_CR40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","volume":"9","author":"LL Lanier","year":"2008","unstructured":"Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495\u2013502. https:\/\/doi.org\/10.1038\/ni1581","journal-title":"Nat Immunol"},{"key":"3448_CR41","doi-asserted-by":"publisher","first-page":"e1004441","DOI":"10.1371\/journal.ppat.1004441","volume":"10","author":"M Luetke-Eversloh","year":"2014","unstructured":"Luetke-Eversloh M, Hammer Q, Durek P et al (2014) Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS Pathog 10:e1004441. https:\/\/doi.org\/10.1371\/journal.ppat.1004441","journal-title":"PLoS Pathog"},{"key":"3448_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.immuni.2015.02.013","volume":"42","author":"J Lee","year":"2015","unstructured":"Lee J, Zhang T, Hwang I et al (2015) Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 42:431\u2013442. https:\/\/doi.org\/10.1016\/j.immuni.2015.02.013","journal-title":"Immunity"},{"key":"3448_CR43","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.4049\/jimmunol.1502438","volume":"196","author":"A Muntasell","year":"2016","unstructured":"Muntasell A, Pupuleku A, Cisneros E et al (2016) Relationship of NKG2C copy number with the distribution of distinct cytomegalovirus-induced adaptive NK cell subsets. J Immunol 196:3818\u20133827. https:\/\/doi.org\/10.4049\/jimmunol.1502438","journal-title":"J Immunol"},{"key":"3448_CR44","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.4049\/jimmunol.1002629","volume":"185","author":"EM de Kruijf","year":"2010","unstructured":"de Kruijf EM, Sajet A, van Nes JGH et al (2010) HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 185:7452\u20137459. https:\/\/doi.org\/10.4049\/jimmunol.1002629","journal-title":"J Immunol"},{"key":"3448_CR45","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1158\/2326-6066.CIR-18-0896","volume":"7","author":"A Muntasell","year":"2019","unstructured":"Muntasell A, Servitja S, Cabo M et al (2019) High numbers of circulating CD57(+) NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2(+) primary breast cancer. Cancer Immunol Res 7:1280\u20131292. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0896","journal-title":"Cancer Immunol Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03448-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03448-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03448-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T03:21:51Z","timestamp":1689996111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03448-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3448"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03448-w","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of INSTITUTO ALEXANDER FLEMING (Resolutions 945\/2017 and 1230\u20135\/2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}